TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7752918
Drug: Doxazosin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (maximum 12 mg/d)
Study: 2182169
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral pulse methotrexate
Study: 22300739
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU weekly
Study: 12404693
Drug: Nicotine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21 mg/day via transdermal patch)
Study: 9109740
Drug: Placebo (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (transdermal patch)
Study: 8674919
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with porfimer sodium and argon‐pumped dye laser
Study: 31838924
Drug: PRGF injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF injection once
Study: 6242074
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin
Study: 10573550
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A, 15 mg retinol equivalent (RE) with TOPV
Study: 10573550
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A, 7.5 mg RE with TOPV
Study: 1672698
Drug: Atenolol (ATN)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (ATN) 100 mg
Study: 7154707
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus (5 mg/m2 i.v. X 4)
Study: 7154707
Drug: Fractionated daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated daily injections (0.5 mg/m2 i.v. q.12 h X 10, course to be repeated after 10‐15 days)
Study: 21934629
Drug: Fimasartan (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan (240 mg) with Hydrochlorothiazide (HCTZ, 25 mg)
Study: 21934629
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 mg) with Fimasartan (240 mg)
Study: 17244766
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg single dose)
Study: 9537487
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of DTaP and commercial Hib vaccine
Study: 9537487
Drug: Booster doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster doses (separate or mixed injections of Hib and DTaP vaccines)
Study: 7702021
Drug: Low-resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-resistant starch (RS) diet (5.2 +/‐ 0.4 g RS)
Study: 28891423
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg every 3 weeks for four doses, then every 12 weeks)
Study: 7799590
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for bile duct fistula
Study: 3259889
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol with repeated bolus doses of alfentanil (group III)
Study: 28716357
Drug: 1000mg omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg omega-3 fatty acids from flaxseed oil supplements, twice a day for 12 weeks
Study: 25193672
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment
Study: 16607544
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy without carbimazole
Study: 9206240
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - Nifedipine tablet
Study: 26890759
Drug: LC-n3-FA (2,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-n3-FA (2,200 mg/day, n=22)
Study: 7519977
Drug: Buprenorphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2 mg/day and 6 mg/day)
Study: 2500941
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of insulin in class B-F diabetic patients
Study: 2500941
Drug: Corticosteroids administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroids administration to the mother
Study: 31648515
Drug: Ultrasound-guided quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided quadratus lumborum (QL) block using 0.25% bupivacaine solution (0.5 ml kg−1)
Study: 31648515
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block using 0.25% bupivacaine solution (0.5 ml kg−1)
Study: 27439031
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 or 5 mg daily for 16 weeks)
Study: 22735866
Drug: Metoprolol IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol IV 5‐15 mg or up to HR ≤ 60 bpm (M)
Study: 22735866
Drug: Diltiazem IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem IV 0.25 to 0.60 mg/kg or up to HR ≤ 60 bpm (D)
Study: 11289345
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate (200 mg/day)
Study: 12474116
Drug: Tandospirone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (60 mg)
Study: 30632208
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (2.5 ml, nebulized once daily for 1 month)
Study: 30632208
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 ml of isotonic saline, nebulized once daily for 1 month)
Study: 9579258
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (20 mg) administered 30 min before surgery
Study: 9579258
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (20 mg) administered after incision
Study: 23297711
Drug: Valsartan (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-320 mg/day)
Study: 19799201
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) with essential keto/amino acids (0.6 g/kg/day) for 24-48 months
Study: 19799201
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD) with highly purified soya protein (0.3 g/kg/day) in a highly energetic nutrient mixture for 24-48 months
Study: 16473754
Drug: Practitioner assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practitioner assessment of treatment (Sham moxibustion)
Study: 16473754
Drug: Practitioner assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practitioner assessment of treatment (Undisclosed treatment)
Study: 10954887
Drug: Nucleoside analogue
Normalized name: Nucleoside analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogue reverse transcriptase inhibitors
Study: 3544187
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist cimetidine (Tagamet, 200 mg three times daily and 400 mg/day)
Study: 3544187
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (antacid and cimetidine)
Study: 30355453
Drug: Trifluridine/tipiracil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days) plus best supportive care
Study: 24871703
Drug: Oxytocin (OXT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OXT) administration
Study: 20979731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar treatment without trimetazidine)
Study: 18832293
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of tibolone (2.5 mg)
Study: 18832293
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of tibolone (2.5 mg)
Study: 6298047
Drug: One shot
Normalized name: Acetaminophen 650 mg in 50 mL ORAL LIQUID [Headache Man No More Pills, One Shot, Headache Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One shot therapy (One shot group)
Study: 30628950
Drug: Hydrocortisone bolus
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone bolus (50 mg every 6 hours)
Study: 19754498
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care in two internal medicine services (UC).
Study: 7836522
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) using epididymal or testicular spermatozoa
Study: 28688129
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg plus ribavirin for 16 weeks (C‐CREST Part C)
Study: 23008337
Drug: Volunteers for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers for treatment (n = 161)
Study: 11044005
Drug: Oral predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral predictive thermometer
Study: 11044005
Drug: Oral glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glass mercury thermometer
Study: 8867395
Drug: HRT (hormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (hormonal replacement therapy)
Study: 8867395
Drug: Non-HRT (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT (no hormone regimen)
Study: 6734056
Drug: 15-mg quazepam
Normalized name: quazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg quazepam tablet in the morning after a night's sleep
Study: 3026039
Drug: Ca-gluconate (1.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-gluconate (1.58 g Ca)
Study: 3026039
Drug: Ossopan (osseino-mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossopan (osseino-mineral complex, 1.58 g Ca)
Study: 3026039
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 24-hour urine excretion
Study: 29055155
Drug: apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 30 mg bid
Study: 26645588
Drug: Mipomersen (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen (50-400 mg, administered subcutaneously or via a 2-h intravenous infusion)
Study: 26645588
Drug: Mipomersen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen (200 mg IV)
Study: 26645588
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg IV)
Study: 20838622
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d), and vitamin B6 (20 mg/d) for 24 months
Study: 20838622
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamins
Study: 12915827
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 to 20 mg)
Study: 2060564
Drug: Caffeine 4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4.2 mg.kg‐1.day‐1
Study: 3178924
Drug: Midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 15 mg
Study: 21807137
Drug: NSAID (ibuprofen)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID (ibuprofen)
Study: 30368796
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of honey
Study: 30368796
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of marmalade (Control)
Study: 30368796
Drug: Honey vs
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey vs Glucose solution
Study: 20075644
Drug: 16-mg ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-mg ER hydromorphone
Study: 20075644
Drug: 32-mg ER
Normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32-mg ER hydromorphone
Study: 20075644
Drug: 64-mg ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64-mg ER hydromorphone
Study: 20075644
Drug: 8-mg IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg IR hydromorphone
Study: 20075644
Drug: 8-mg ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg ER hydromorphone (milled)
Study: 2241001
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg/day)
Study: 9716159
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg rHDL/kg body weight
Study: 9716159
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rHDL/kg body weight
Study: 8480959
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 to 80 mg/d)
Study: 29273578
Drug: Dasiglucagon 0.6
Normalized name: DASIGLUCAGON 0.6MG/0.6ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.6 mg
Study: 25063211
Drug: SD-FBP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-FBP (standard dose, 120 kV, 6 ± 1 mGy)
Study: 20080983
Drug: Modafinil, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil, 400 mg
Study: 16796223
Drug: Caffeine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine, 600 mg
Study: 14671195
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg exemestane daily for 10 days
Study: 8792690
Drug: 10 MU
Normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group A)
Study: 8792690
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group B)
Study: 17368645
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution
Study: 15876453
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control - CO)
Study: 24107880
Drug: Pantocalcin (hopantenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantocalcin (hopantenic acid preparation)
Study: 10759359
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg bid
Study: 10759359
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 50,000 IU given in three divided doses
Study: 1295136
Drug: Amodiaquine therapy
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine therapy (25 mg base/kg over 3 days)
Study: 21198234
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of transference work
Study: 12140795
Drug: RC-Cornet(R) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC-Cornet(R) therapy group (combined-PEP therapy)
Study: 12140795
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy group (theophylline, salmeterol, ipratropiumbromide, systemic steroids)
Study: 10430331
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg/week, adjusted up to 22.5 mg/week
Study: 2250563
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (CT) 100 UI administered by nasal route
Study: 31596127
Drug: Artificial pancreas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial pancreas with learning algorithm (daily updates of basal rates and carbohydrate ratios)
Study: 10778882
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet with soy protein foods (33 g/d soy protein)
Study: 7870896
Drug: Desipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (75 mg daily)
Study: 3530865
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg at bedtime for 6 months)
Study: 3530865
Drug: Ranitidine (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (open treatment)
Study: 17398320
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no adjuvant therapy)
Study: 26308112
Drug: Groups 1-4
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1-4 (concomitant administration)
Study: 26308112
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Vaqta, PedvaxHIB, and Infanrix
Study: 26308112
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration
Study: 25473191
Drug: Lubiprostone (Amitza),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (Amitza), orally twice a day for six days
Study: 11126207
Drug: Orlistat treatment
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat treatment
Study: 11952580
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy (6 MIU intramuscularly every day for 2 weeks, then three times a week for 14 weeks and finally twice a week for 88 weeks)
Study: 7698517
Drug: Glipizide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (2.5 mg/day)
Study: 2744191
Drug: Wallace catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wallace catheter (H.G. Wallace Limited, Colchester, England)
Study: 23305820
Drug: 12-step facilitation
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step facilitation for stimulant abusers
Study: 21969930
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 250 mcg twice daily for four weeks
Study: 21969930
Drug: Open-label treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label treatment with fluticasone propionate 250 mcg/salmeterol 50 mcg
Study: 18524134
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) solutions (light, medium, heavy molecular weight)
Study: 10443327
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected 5 minutes before meals
Study: 10443327
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected 30 minutes before meals
Study: 760446
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin therapy
Study: 760446
Drug: Intermittent heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent heparin therapy
Study: 760446
Drug: Overall group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall group (both therapies)
Study: 22065255
Drug: SMM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMM plus opioid dependence counseling during extended treatment
Study: 9864127
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR) with Morgan therapeutic lens (MTL)
Study: 9864127
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR) without Morgan therapeutic lens (MTL)
Study: 9864127
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS Plus) without Morgan therapeutic lens (MTL)
Study: 9864127
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (NSS) without Morgan therapeutic lens (MTL)
Study: 9864127
Drug: Ocular irrigation
Normalized name: Sodium chloride 9 mg/mL solution for ocular irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular irrigation solutions (LR, BSS Plus, NSS)
Study: 8919570
Drug: Colorectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer screening (various modalities); specific details on dosage and duration not available.
Study: 2191990
Drug: Inhaled bitolterol
Normalized name: bitolterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bitolterol (three puffs, 1110 micrograms)
Study: 11279374
Drug: NaCl 5
Normalized name: NaCl 5 MG/ML Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 5 ml (Control Group F)
Study: 8193000
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of patch vs primary closure
Study: 28225446
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT) alone
Study: 19244043
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy (CRT)
Study: 27084997
Drug: Udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 100 mg in healthy subjects
Study: 27084997
Drug: Udenafil 75
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 75 mg in patients with moderate HI
Study: 9469674
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration 24 hours after chemotherapy (standard arm)